RecruitingPhase 2NCT07831369

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

Sponsor

Inova Health Care Services

Enrollment

52 participants

Start Date

Sep 4, 2026

Study Type

INTERVENTIONAL

Conditions

Glioblastoma Astrocytoma, IDH-Mutant, Grade 4

Summary

The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas

Eligibility

Min Age: 18 YearsMax Age: 98 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Irinotecan, a drug called Simvastatin, and others for people with astrocytoma, idh-mutant, grade 4 and glioblastoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 98 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.